Posts tagged Chair of Aileron’s SAB
Michael B. Kastan, M.D., Ph.D.

Michael B. Kastan, M.D., Ph.D., is the William and Jane Shingleton Professor of Pharmacology and Cancer Biology and Professor of Pediatrics at Duke University and serves as the Executive Director of the Duke Cancer Institute. A Morehead Scholar graduate of the University of North Carolina, he earned M.D. and Ph.D. degrees from the Washington University School of Medicine and did his clinical training in Pediatrics and Pediatric Hematology-Oncology at Johns Hopkins. He was a Professor of Oncology, Pediatrics, and Molecular Biology at Johns Hopkins prior to becoming Chair of the Hematology-Oncology Department and later Cancer Center Director at St. Jude Children’s Research Hospital, before moving to Duke in 2011. He is a Pediatric Oncologist and a cancer biologist; his laboratory research concentrates on DNA damage and repair, tumor suppressor genes, and causes of cancer related to genetic predisposition and environmental exposures. His discoveries have made a major impact on our understanding of both how cancers develop and how they respond to chemotherapy and radiation therapy and his publications reporting the roles of p53 and ATM in DNA damage signaling are among the most highly cited publications in the biomedical literature of the past two decades. He has received numerous honors for his highly cited work, including election to the National Academy of Sciences, National Academy of Medicine, the American Academy of Arts and Sciences, and receiving the AACR-G.H.A. Clowes Memorial Award for outstanding contributions to basic cancer research. He has served as Chairman of the Board of Scientific Counselors of the National Cancer Institute (NCI), on the Boards of Directors of the American Association for Cancer Research (AACR) and the American Association of Cancer Institutes (AACI), as Editor-in-Chief of the journal Molecular Cancer Research, and as Editor of the textbook Clinical Oncology. He also serves on the scientific advisory boards of both Stand-Up-to-Cancer (SU2C) and the V Foundation.


Read More
Loren D. Walensky, M.D., Ph.D.

Loren D. Walensky, M.D., Ph.D., is a chemical biologist and pediatric oncologist, whose innovative work in creating stapled peptides for use in cancer and other disease applications contributed to the founding of Aileron Therapeutics. His ongoing work employs this groundbreaking peptide-stapling strategy to produce diverse anticancer peptides to deactivate disease-causing apoptotic and transcriptional pathways in a variety of human tumors, and he also remains deeply committed to pediatric oncology care. Dr. Walensky joined the Dana-Farber and Harvard Medical School faculty as Instructor of Pediatrics in 2003, founded his independent research laboratory as Assistant Professor in 2006, and was promoted to Associate Professor in 2011 and Full Professor in 2016. Dr. Walensky is the recipient of numerous awards including an NIH Director’s Transformative Research RO1 Award, a Burroughs Wellcome Career Award in the Biomedical Sciences, the E. Mead Johnson Award for Pediatric Research, and an NCI Outstanding Investigator R35 Award. He is a member of the American Society for Clinical Investigation, the Society for Pediatric Research, and the American Pediatric Society. Dr. Walensky received his M.D and Ph.D. degrees from the Johns Hopkins University School of Medicine.

Read More